Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs Ltd announced the issuance of unquoted equity securities, including 110,528 service rights and 663,168 performance rights, under an employee incentive scheme. This move is likely aimed at enhancing employee engagement and aligning staff interests with company goals, potentially impacting the company’s operational dynamics and stakeholder relations.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is involved in offering a range of diagnostic services and tests, serving various medical and healthcare needs across Australia.
Average Trading Volume: 785,388
Technical Sentiment Signal: Buy
Current Market Cap: A$546.7M
For detailed information about ACL stock, go to TipRanks’ Stock Analysis page.